Barinthus Biotherapeutics plc (2AB.F)

1.9200 -0.0300 (-1.54%) At close: 08:06AM CEST

Barinthus Biotherapeutics plc

Zeus Building
Unit 6-10 Rutherford Avenue Harwell
Didcot OX11 0DF
United Kingdom
44 1865 818 808
https://www.barinthusbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 130

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. William J. Enright MBA	CEO & Director	903.52k	N/A	1962
Dr. Nadege Pelletier Ph.D.	Chief Scientific Officer	553.13k	N/A	1979
Mr. Graham Griffiths	Chief Business Officer	486.72k	N/A	1980
Ms. Sarah Gilbert	Co-Founder	45.65k	N/A	N/A
Mr. Adrian Hill Ph.D.	Co-Founder & Scientific Advisor	57.42k	N/A	N/A
Ms. Gemma Brown	CFO & Company Secretary	N/A	N/A	1991
Ms. Elizabeth Eagling-Vose M.B.A.	Head of Clinical Operations	N/A	N/A	N/A
Bernie McDonald	Head of IP	N/A	N/A	N/A
Geoffrey Lynn	Senior Vice President of Synthetic Immunotherapies	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Corporate Governance

Barinthus Biotherapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.